Royal UNIBREW A/S
Share buy-back program
Share buy-back program
COMPANY ANNOUNCEMENT NO 17/2025 - March 31, 2025
On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025.
The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016.
The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The total transaction value of the share buy-backs in the period will not exceed DKK 250m.
The following transactions on Nasdaq Copenhagen A/S have been made under the program:
| Number of Shares | Average purchase price DKK | Transaction value, DKK | |
| Accumulated, last announcement | 57,947 | 548.88 | 31,806,110 |
| March 24, 2025 | 5,000 | 540.98 | 2,704,886 |
| March 25, 2025 | 7,000 | 535.16 | 3,746,133 |
| March 26, 2025 | 8,000 | 531.36 | 4,250,848 |
| March 27, 2025 | 3,000 | 550.99 | 1,652,984 |
| March 28, 2025 | 3,000 | 551.60 | 1,654,795 |
| Total accumulated under the program | 83,947 | 545.77 | 45,815,756 |
With the transactions stated above Royal Unibrew owns a total of 217,342 shares, corresponding to 0.4% of the share capital. The total amount of shares in the company is 50,200,000, including treasury shares.
For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04
Encl.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG3.4.2025 02:13:00 CEST | Press release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
CRUSHON AI CORP3.4.2025 02:05:57 CEST | Press release
Crushon AI Adds Target Play for Spicy AI and NSFW Character Chats
Appian Capital Advisory2.4.2025 22:34:00 CEST | Press release
Appian completes sale of MVV to Baiyin Nonferrous for US$420 million
Nokia Oyj2.4.2025 21:45:00 CEST | Press release
Nokia completes the share buyback program launched in November 2024
Nokia Oyj2.4.2025 21:30:00 CEST | Press release
Nokia Corporation: Repurchase of own shares on 02.04.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom